Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences (NASDAQ:PCRX) reported publication of positive two-year Phase 1 data for PCRX-201, its investigational locally administered gene therapy for moderate-to-severe knee osteoarthritis, in Annals of the Rheumatic Diseases. A single intra-articular knee injection of PCRX-201 was well tolerated over 104 weeks.
The open-label Phase 1 trial enrolled 72 adults aged 30–80 years in two parts across low, middle, and high doses, with Part 2 adding methylprednisolone pretreatment. Exploratory outcome measures showed improvements in pain, stiffness, and function across all dose cohorts among participants who remained in the study. Glucocorticoid pretreatment was associated with a lower rate of joint effusion and greater clinical improvement and has been incorporated into Pacira’s ongoing Phase 2 ASCEND trial, which has initiated Part B enrollment and targets a first topline readout by year-end 2026.
Pacira BioSciences (Nasdaq:PCRX) reported second quarter 2026 total revenue of $192.4 million, up 6% year over year. GAAP net income was $4.7 million, or $0.12 per share, versus a $4.8 million loss a year ago. Non-GAAP net income was $29.5 million and adjusted EBITDA was $48.7 million.
EXPAREL net product sales were $147.8 million (+3%), ZILRETTA sales were $32.6 million (+4%), and iovera° sales were $6.8 million (+22%). Pacira closed the divestiture of its iovera° business to Zimmer Biomet, receiving $73.6 million at closing and eligibility for up to $140 million in total consideration.
According to Pacira, UnitedHealthcare now provides separate reimbursement for EXPAREL in outpatient settings. The company advanced its PCRX-201 gene therapy program into a scalable commercial manufacturing process and Part B enrollment of the Phase 2 ASCEND study. Pacira ended the quarter with $251.0 million in cash and updated 2026 total revenue guidance to $735–$760 million, adjusting for the iovera° sale, while reiterating EXPAREL sales and margin guidance.
Pacira BioSciences (NASDAQ:PCRX) released results from its national Standing Strong: The Impact of Pain on America's Workforce survey of 1,000 full-time U.S. workers whose jobs require time on their feet, conducted online from April 17 to May 3, 2026. The survey, which reflects only respondents’ experiences and opinions, found that 85% reported work-related orthopedic pain at least sometimes, and 41% often or all the time. More than half reported lost income due to pain, and 55% would choose a less physical career, rising to 73% among active military.
Knee pain was the most common complaint, with 56% reporting chronic knee pain. Among those with knee pain as their primary concern, 66% said it harms social life and relationships. Pacira highlighted strong interest in long-lasting, non-opioid options: among respondents with chronic knee pain, 24% used prescription opioids, yet 98% would consider a long-lasting, non-opioid treatment. The company underscored ZILRETTA, an extended-release intra-articular corticosteroid for osteoarthritis knee pain, alongside EXPAREL and iovera, and outlined key ZILRETTA safety information, including contraindications, serious and common side effects, and the fact that benefits and risks of repeat injections have not been demonstrated.
Pacira BioSciences (NASDAQ:PCRX) reported a successful transition of PCRX-201, its investigational locally administered gene therapy for osteoarthritis of the knee, to a U.S.-based, scalable commercial manufacturing process designed to support future registrational development and commercialization. Availability of drug product from this process enabled enrollment of the first patient in Part B of the Phase 2 ASCEND study, while enrollment in Part A concluded in June with topline data expected by the end of 2026.
The two-part ASCEND trial will enroll about 135 patients, randomizing them 1:1:1 to two PCRX-201 dose levels or saline, all with corticosteroid pretreatment. The primary endpoint is safety over 52 weeks, with secondary pain and function outcomes through 52 weeks and five-year follow-up. According to Pacira, the process change did not delay ASCEND and further validates its high-capacity adenovirus (HCAd) platform, supporting PCRX-201’s progression alongside existing RMAT and ATMP designations and previously reported three-year durability and tolerability data.
Pacira BioSciences (Nasdaq: PCRX) announced it will report its second quarter 2026 financial results after U.S. market close on Tuesday, August 4, 2026. A live conference call and webcast will follow at 4:30 p.m. ET, with pre-registration required for telephone Q&A participation and a replay available on the company’s investor website for about two weeks.
Pacira BioSciences (Nasdaq:PCRX) granted inducement equity awards on July 2, 2026 to ten new employees under its 2014 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Four employees received stock options for 9,200 shares and ten employees received 18,200 restricted stock units, each with multi-year vesting tied to continued employment.
Pacira BioSciences (NASDAQ:PCRX) announced that UnitedHealthcare now provides separate reimbursement for EXPAREL across outpatient settings, including hospital outpatient departments and ambulatory surgery centers.
According to Pacira, this covers about 40 million UnitedHealthcare members and contributes to roughly 150 million covered lives with separate EXPAREL reimbursement nationwide.
Pacira BioSciences (Nasdaq:PCRX) agreed to divest its iovera° cryoneurolysis pain-treatment business to Zimmer Biomet (NYSE:ZBH). Pacira will receive up to $140 million, including $70 million upfront and up to $70 million in revenue-based milestones through December 31, 2031.
The companies will also collaborate on a spasticity program, with potential extra compensation for Pacira, and Pacira plans to use upfront proceeds to pay down its senior secured revolving credit facility. Closing is expected in Q3 2026, subject to customary conditions.
Pacira BioSciences (Nasdaq:PCRX) announced that, based on preliminary results from its 2026 Annual Meeting of Stockholders, all three company director nominees — Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans — were elected to the board.
Final results will be certified and filed on Form 8-K with the SEC.
Pacira BioSciences (Nasdaq:PCRX) urges stockholders to vote the BLUE proxy card for its three director nominees ahead of the June 9, 2026 annual meeting. Independent advisors ISS, Glass Lewis and Egan-Jones recommend supporting Pacira’s slate. Pacira highlights record 2025 revenue and margins, Q1 2026 EXPAREL, ZILRETTA and iovera° growth, and upcoming 2026 clinical readouts as reasons to maintain its current board and 5x30 strategy.